ADAM17 and familial pancreatic carcinoma: However, despite its important role in tumour invasion and progression in pancreatic cancer (Ringel et al, 2006) and other types of tumours (Arribas et al, 2006; Mochizuki and Okada, 2007), immunohistochemical expression of ADAM17 correlates significantly neither with clinical and pathological data nor with ALCAM expression in pancreatic cancer.